NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma<
04 Sep 2018

Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma

Company prepares to initiate late stage clinical development for its flagship drug in choroidal melanoma next year.
06 Aug 2018

Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis

Laboratoris Sanifit S.L., today announced the completion of enrollment of its Phase 2b CaLIPSO clinical trial investigating Sanifit’s lead candidate SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).
31 Jul 2018

Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period

Takeda Pharmaceutical Company Limited and TiGenix NV today announced that Takeda has acquired all outstanding ordinary shares and warrants of TiGenix following the expiration of the squeeze-out period.
Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting<
25 Jul 2018

Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting

Interim data presented at ASRS show that in an expanded set of subjects AU-011 continues to be well-tolerated with no related serious adverse events.
10 Jul 2018

CorWave’s next-generation LVAD, Neptune, receives funding

The CALYPSO Research and Development (R&D) program, with a total budget of 25 million euros over 4 years, will be partially financed with 14 million euros support from the Program d'Investissements d'Avenir (Future Investments Program), managed by the Secrétariat Général pour l’Investissement (General Secretariat for Investment – SGPI) and operated by Bpifrance.
27 Jun 2018

BioClin Therapeutics Appoints Scott Myers as Chairman to its Board of Directors

BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need, announced today the appointment of Scott D. Myers as chairman of   Board of Directors.
Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma<
17 Jun 2018

Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma

AU-011 is an investigational, first-in-class targeted therapy in development for the treatment of primary choroidal melanoma.
12 Jun 2018

Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board

Vivet Therapeutics today announced the appointment of Eduardo Bravo as Chairman of its Board of Directors.

10 May 2018

BioClin Therapeutics, Inc.,Completes $50 Million Series B Financing with Addition of New Investors

BioClin Therapeutics, Inc., announced today expansion of its Series B financing to $50 million to broaden its clinical development activities.
03 Apr 2018

CorWave is set to receive about €3 million in financing through France’s Worldwide Innovation Challenge for its NovaPulse program, a mini-invasive solution for cardiac support

CorWave announced today that it has been awarded almost €3 million in financing for its R&D program NovaPulse in the Silver Economy category.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка